| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | ARGX-109 Multiple autoimmune indications / early-stage pipeline expansion (program-level) | IND | — | Biologics | Immunology | ||
IND Submission example | ARGX-109 Multiple autoimmune indications / early-stage pipeline expansion (program-level) | IND | — | Biologics | Immunology | ||
IND Submission example | ARGX-109 Multiple autoimmune indications / early-stage pipeline expansion (program-level) | IND | — | Biologics | Immunology |
Recent Updates
Recently added Catalysts
argenx SE$907.51
-20.09 (-2.17%)
C 56Pipeline Score Richly Valued Biotech · Commercial
Market Cap
50.32 B
EPS
21.10
P/E Ratio
41.18 $
Value Trade
253.48 M
-1.63 %
Week
0.18 %
1 Month
-5.07 %
3 Month
-12.2 %
6 Month
197.06 %
5 Year
4,405.36 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
291.64 K
52 Week Range
510.06 - 934.62
% held by Insiders
0.29 %
% held by Institutions
46.32 %
Enterprise Value
45.93 B
Total Shares
61.88 M
Short %
2.38 %
Float Shares
61.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for argenx SE
723Total events
11Upcoming
240Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 11
Jul 23, 2026
T2Quarterly Update
Half Year and Second Quarter 2026 Financial Results and Business Update
TBD
T2Oral Presentation
Detailed results from ADAPT SERON to be presented at upcoming medical meeting
TBD
T1Full Results
Comprehensive analysis of UplighTED data to be conducted after close out and database lock
TBD
T1FDA Filing Accepted
Plans to share ADAPT SERON results with FDA and seek label expansion to include AChR-Ab seronegative gMG
TBD
T1Full Results
Detailed results from Phase 1b study of ARGX-119 to be presented at a future medical meeting
Event history 712
Q3 2026
◆sNDA SubmissionEfgartigimodApprovedRegulatory Filing
sBLA submission for VYVGART in oMG expected by end of Q3 2026
ocular myasthenia gravissource ↗
Q3 2026
◆Topline ReadoutEfgartigimodApprovedClinical Data
ALKIVIA topline results expected in second half of 2026
Graves' disease (GD)source ↗
Q3 2026
●Trial InitiationadimanebartTrial
Adimanebart CMS registrational study expected to start Q3 2026
congenital myasthenic syndromes (CMS)source ↗
Q3 2026
◆Topline ReadoutEfgartigimodApprovedClinical Data
Topline results for ALKIVIA (myositis) expected Q3 2026
autoimmune inflammatory myopathies (AIM/myositis)source ↗
Jun 23, 2026
●R&D DayPresentation
R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis Webinar
Jun 6, 2026
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of cross-indication safety analysis at EULAR 2026
multiple autoimmune diseasessource ↗
Jun 5, 2026
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of ALKIVIA+ long-term safety and efficacy results at EULAR 2026
myositissource ↗
Jun 3, 2026
▲Oral PresentationEfgartigimodApprovedPresentation
Oral presentation of RHO+ long-term efficacy and safety results at EULAR 2026
Sjogren's diseasesource ↗
Jun 2026
◆Additional DataEmpasiprubartClinical Data
52-week efficacy analysis for VARVARA (DGF) expected mid-year 2026
delayed graft function (DGF)source ↗
May 12, 2026
◆Oral PresentationPresentation
argenx CEO to present at BofA Securities 2026 Health Care Conference
May 10, 2026
◆PDUFA DateEfgartigimodApprovedRegulatory Filing
PDUFA target action date for seronegative gMG
anti-acetylcholine receptor antibody negative (AChR-Ab-) generalized myasthenia gravis (gMG)source ↗
May 8, 2026
▲Supplemental ApprovalEfgartigimodApprovedFDA Decision
FDA approved label expansion for VYVGART and VYVGART Hytrulo for all serotypes of adult gMG
generalized myasthenia gravissource ↗
Drug Pipeline Intelligence
C56
Pipeline Score $4.8B
Pipeline ValueRichly Valued
Valuation Signal18
Drugs Scored0.1x
rNPV / MCap Top 86%
Large Pharma (rank 128 of 905)
Percentile Rankargenx SE carries a moderate pipeline score (56/100), with $4.8B risk-adjusted pipeline value, led by Empasiprubart in Multifocal Motor Neuropathy (MMN) (Phase 3), across $97B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| empasiprubart Monoclonal antibody | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | NCT06920004 | 51% | $1.2B | RECRUITING | 378 | AVERAGE | B (69) | Sep 1, 2030 | MODERATE_RISK | LOW Jun 12, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VYVGART | AChR-Ab seronegative gMG | Phase 3 | 2025-08-25 | |||
VYVGART | AChR-Ab seronegative gMG | Phase 3 | 2025-08-25 | |||
VYVGART | AChR-Ab seronegative gMG | Phase 3 | 2025-08-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
argenx SE (ARGX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ARGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ARGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARGXargenx to Host Autoimmune Myositis R&D Webinar
argenx is hosting a webinar on June 23, 2026, focusing on autoimmune myositis and their advancements in FcRn leadership. The event will feature key opinion leaders from prestigious institutions discussing the latest research and developments. A live webcast will be available, along with supporting materials on their website.
Read more →ARGXargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Argenx presented new data on efgartigimod at EULAR 2026, demonstrating its long-term benefits in myositis and Sjogren's disease. The ALKIVIA+ study showed sustained improvements in myositis patients, while the RHO+ study confirmed maintenance of response in Sjogren's disease. Efgartigimod's safety profile remained consistent across various autoimmune conditions.
Read more →ARGXargenx to Host Myositis R&D Webinar on June 23, 2026
argenx announced a webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' scheduled for June 23, 2026. This event is part of a mini-series aimed at showcasing the company's research and development strategy. The webinar will feature discussions on myositis, including disease biology and the ALKIVIA clinical program for efgartigimod.
Read more →ARGXargenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences
Read more →ARGXargenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx announced that the FDA has approved a label expansion for VYVGART and VYVGART Hytrulo, allowing their use in all adult patients with generalized myasthenia gravis (gMG), including those without detectable anti-AChR antibodies. This approval is based on the Phase 3 ADAPT SERON study, which demonstrated significant symptom improvements in patients treated with VYVGART. The expansion aims to meet the needs of a broader range of gMG patients, simplifying treatment decisions for clinicians.
Read more →ARGXargenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx SE reported a robust first quarter for 2026, achieving $1.3 billion in global product net sales, marking a 63% increase year-over-year. The company is optimistic about the upcoming PDUFA date for anti-AChR antibody negative gMG on May 10, 2026, and is advancing its pipeline with several candidates expected to enter registrational studies. argenx aims to treat 50,000 patients globally by 2030 and is expanding its leadership in FcRn therapies.
Read more →ARGXargenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
argenx SE has announced the appointment of Karen Massey as Chief Executive Officer, succeeding Tim Van Hauwermeiren, who will now serve as Chairperson of the Board. The transition follows a successful Annual General Meeting where shareholders approved all agenda items. Massey, who joined the company in March 2023, is expected to lead the next phase of growth for argenx.
Read more →ARGXargenx to Present at BofA Securities 2026 Health Care Conference
argenx announced that CEO Karen Massey will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. The presentation will focus on the company's advancements in treating severe autoimmune diseases. A live webcast will be available, along with a replay for 30 days post-event.
Read more →ARGXargenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
argenx has announced a conference call scheduled for May 7, 2026, to discuss its first quarter financial results and provide a business update. The call will be accessible via a webcast on the company's website, with a replay available for one year. This event highlights argenx's ongoing commitment to addressing severe autoimmune diseases.
Read more →ARGXargenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
argenx SE presented new data for VYVGART at the 2026 AAN Annual Meeting, highlighting its potential for broader use in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The data indicates VYVGART's effectiveness across various MG subtypes and shows promise for early clinical improvement in CIDP patients. The company aims to expand VYVGART's reach to more patients suffering from these conditions.
Read more →ARGXargenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGAR
Argenx SE announced new data supporting the expanded use of VYVGART for treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) during the 2026 American Academy of Neurology Annual Meeting. The findings, which include presentations on adimanebart for congenital myasthenic syndromes, highlight significant advancements in the company’s neuromuscular pipeline. VYVGART is expected to benefit a broader range of MG patients, potentially improving their quality of life. The research aims to address the complexities and challenges faced by patients living with these severe autoimmune diseases.
Read more →ARGXargenx announces Annual General Meeting of Shareholders on May 6, 2026
argenx SE has announced its Annual General Meeting of shareholders to be held on May 6, 2026, in Amsterdam. The meeting will cover key agenda items including the adoption of the 2025 annual accounts and an advisory vote on the remuneration report. Notably, Jim Daly will retire as a non-executive director, marking a significant leadership change.
Read more →ARGXargenx announces Annual General Meeting of Shareholders on
argenx SE has announced its Annual General Meeting of shareholders, which will take place on May 6, 2026, in Amsterdam. The meeting will cover recurrent agenda items including the discussion of the 2025 annual accounts and changes to the Board of Directors, specifically the retirement of Jim Daly. The company appreciates Daly's contributions during his tenure and is currently planning for his succession. Shareholders are encouraged to participate either in person or via proxy voting.
Read more →ARGXargenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potenti
argenx SE is set to present new data at the 2026 AAN Annual Meeting that could significantly improve treatment options for patients with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Positive findings from the Phase 3 ADAPT OCULUS study demonstrate the efficacy of VYVGART, while additional research on empasiprubart and adimanebart will further support the company's innovative pipeline. Real-world insights indicating the successful transition of patients from conventional therapies to VYVGART are also included in the presentations. These developments highlight argenx's commitment to advancing patient outcomes in underserved autoimmune conditions.
Read more →ARGXargenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
argenx reported strong financial results for 2025, achieving $4.2 billion in net sales and marking its first year of operating profitability. The company announced positive Phase 3 results for VYVGART, which is set for label expansion. Looking ahead, argenx aims to treat 50,000 patients globally by 2030 and continues to advance its pipeline with multiple candidates in development.
Read more →ARGXargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
argenx SE announced positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in adults with ocular myasthenia gravis. The trial met its primary endpoint, demonstrating significant improvements in patient-reported outcomes. VYVGART was well tolerated, with no new safety concerns identified. This study is the first to evaluate a targeted therapy specifically for ocular myasthenia gravis.
Read more →ARGXargenx to Present at TD Cowen 46th Annual Healthcare Conference
argenx announced that COO Karen Massey will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026. The event will be accessible via a live webcast, with a replay available for 30 days. argenx focuses on developing innovative therapies for severe autoimmune diseases.
Read more →ARGXargenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Read more →ARGXargenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
argenx announced that the FDA has accepted its supplemental Biologics License Application for VYVGART, targeting AChR-Ab seronegative generalized myasthenia gravis. The application received priority review status, with a PDUFA date set for May 10, 2026. The decision is supported by positive Phase 3 trial results showing significant improvements in patient outcomes.
Read more →ARGXargenx Highlights 2026 Strategic Priorities Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues
argenx reported its preliminary financial results for the full-year 2025, highlighting a significant global product net sales growth of 90% year-over-year, amounting to $4.15 billion. The company focuses on advancing its strategic priorities for 2026, including the launch of new FcRn medicines and a commitment to treat 50,000 patients globally. Furthermore, four registrational readouts are anticipated in 2026, alongside continued pipeline expansion with new candidates entering clinical stages. Recent organizational transitions, including leadership changes, underscore the company's ongoing commitment to growth and innovation.
Read more →ARGXargenx Highlights 2026 Strategic Priorities
argenx Highlights 2026 Strategic Priorities
Read more →ARGXargenx to Present at 44th Annual J.P. Morgan Healthcare Conference
argenx announced that CEO Tim Van Hauwermeiren will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via a live webcast, with a replay available for 30 days. This event highlights argenx's commitment to advancing treatments for severe autoimmune diseases.
Read more →ARGXargenx Announces Leadership Transition Marking Next Evolution of Growth
argenx SE has announced a leadership transition, with Karen Massey moving from COO to CEO and Tim Van Hauwermeiren transitioning to Chairman of the Board. This change is part of the company's strategy for future growth and is subject to shareholder approval. The current Chairman, Peter Verhaeghe, will retire after years of service. Both leaders express optimism about the company's direction.
Read more →ARGXargenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
argenx announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod SC for thyroid eye disease due to a recommendation from the Independent Data Monitoring Committee based on futility. Despite this setback, the drug demonstrated a favorable safety profile. A comprehensive analysis of the data will be conducted to gain insights for future research.
Read more →ARGXargenx Announces Results of Extraordinary General Meeting of Shareholders
argenx SE announced the results of its Extraordinary General Meeting held on November 18, 2025. The sole agenda item, a remuneration policy, was overwhelmingly approved by shareholders with 95.67% voting in favor. Additionally, 91.1% of the company's share capital participated in the voting, reflecting strong support for the company's governance.
Read more →ARGXargenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subt
argenx SE has presented new data showcasing the efficacy and safety of its drug VYVGART for patients with generalized myasthenia gravis (gMG) at the AANEM and MGFA meetings. Key findings from the Phase 3 ADAPT SERON trial confirm the drug’s effectiveness in seronegative AChR-Ab patients, highlighting significant functional improvements. Additionally, a real-world study demonstrated reduced steroid use among patients treated with VYVGART, indicating the drug's broad potential benefits. These results aim to redefine treatment standards for gMG patients, emphasizing argenx's commitment to improving patient outcomes.
Read more →ARGXargenx Reports Third Quarter 2025 Financial Results and Provides Business Update
argenx SE reported impressive third quarter financial results for 2025, with global product net sales reaching $1.13 billion. The company is on track to submit a supplemental Biologics License Application for seronegative generalized myasthenia gravis by the end of the year and anticipates five registrational study readouts in 2026. The CEO highlighted the ongoing commitment to innovation and expanding treatment options for patients with severe autoimmune diseases.
Read more →ARGXargenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Argenx presented new data on VYVGART at the 2025 AANEM and MGFA meetings, showcasing its efficacy and safety for generalized myasthenia gravis (gMG) patients. The data included pivotal Phase 3 results from the ADAPT SERON trial and real-world analyses demonstrating reduced steroid use. These findings highlight VYVGART's potential to improve patient outcomes across various gMG populations.
Read more →ARGXargenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Read more →ARGXargenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
argenx SE will present key data for its therapies VYVGART and empasiprubart at the 2025 AANEM Annual Meeting and MGFA Scientific Session in San Francisco. The presentations will cover advancements in treating various neuromuscular diseases, showcasing the company's commitment to innovation and improving patient outcomes. This event highlights argenx's ongoing clinical development efforts.
Read more →ARGXargenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx SE has announced an Extraordinary General Meeting of shareholders scheduled for November 18, 2025, in Amsterdam. The meeting will address the adoption of a revised remuneration policy. Shareholders are encouraged to attend in person or vote by proxy, with relevant documents available on the company's website.
Read more →ARGXargenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
argenx announced positive topline results from the ADAPT SERON study of VYVGART in AChR-Ab seronegative gMG patients. The study met its primary endpoint, showing significant improvement in MG-ADL scores compared to placebo. argenx plans to submit an sBLA to the FDA for label expansion. VYVGART was well tolerated, aligning with its established safety profile.
Read more →ARGXargenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx will host a webinar on September 16, 2025, focusing on its MuSK agonist program, ARGX-119. The event aims to discuss the drug's potential in treating neuromuscular diseases such as congenital myasthenic syndromes, ALS, and SMA. This webinar is part of a mini-series showcasing argenx's R&D strategy and pipeline.
Read more →ARGXargenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Argentx has partnered with tennis champion Monica Seles to raise awareness of myasthenia gravis (MG). Seles, who has been living with MG, aims to empower patients and connect them with support resources. The initiative, 'Go for Greater', will be highlighted at the 2025 U.S. Open, emphasizing the importance of community and understanding for those affected by MG.
Read more →ARGXargenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Read more →ARGXargenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
Read more →ARGXargenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consi
argenx announced the advancement of ARGX-119 into a registrational study for DOK7 congenital myasthenic syndromes after positive results from a Phase 1b study. This study confirmed proof-of-concept and established a favorable safety profile for the novel treatment. DOK7 congenital myasthenic syndromes are rare and currently lack approved therapies, making the potential impact of ARGX-119 significant. The drug is part of argenx's Immunology Innovation Program and aims to enhance the treatment landscape for neuromuscular diseases.
Read more →ARGXargenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART SC, first-and-only IgG Fc-antibody fragment which specifically targets the neo
argenx SE has received European Commission approval for VYVGART subcutaneous injection, making it an approved monotherapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The approval is based on positive results from the ADHERE clinical trial, which demonstrated significant clinical improvement in 66.5% of patients. VYVGART SC is noted as the first therapy with a novel mechanism of action for CIDP in over three decades and will be available across all EU member states as well as in Iceland, Liechtenstein, and Norway.
Read more →ARGXargenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease ALKIVIA data demonstrate significant improvement in muscle strength and physica
argenx presented positive Phase 2 results for efgartigimod at EULAR 2025, highlighting significant improvements in muscle strength and physical function in myositis patients. The FDA has granted Fast Track designation for efgartigimod in treating primary Sjogren's disease. Data indicated that efgartigimod met primary endpoint with a mean Total Improvement Score significantly higher than placebo. The ongoing ALKIVIA and UNITY studies aim to further investigate efgartigimod's efficacy and safety.
Read more →ARGXargenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Read more →ARGXargenx Announces Results of Annual General Meeting of Shareholders
argenx SE announced the results of its Annual General Meeting of shareholders, held on May 27, 2025. A total of 91.1% of the company's share capital was represented. Most agenda items received majority approval, excluding the remuneration policy, which fell short of the required majority. This outcome suggests mixed sentiments among shareholders regarding executive compensation.
Read more →ARGXargenx Reports First Quarter 2025 Financial Results and Provides Business Update
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Read more →ARGXargenx to Present at BofA Securities 2025 Health Care Conference
argenx to Present at BofA Securities 2025 Health Care Conference
Read more →ARGXargenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Read more →ARGXargenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART is first-and-only targeted IgG Fc-antibody fragment for C
argenx has announced a positive opinion from the CHMP for its VYVGART (efgartigimod alfa) subcutaneous injection, aimed at treating adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This recommendation, if approved by the European Commission, would mark the introduction of a novel treatment in Europe for CIDP patients in three decades. The recommendation is based on results from the ADHERE clinical trial which demonstrated significant clinical improvement in a large percentage of patients. VYVGART is positioned as an important new option for those who have not responded adequately to existing therapies.
Read more →ARGXargenx Announces Annual General Meeting of Shareholders on
argenx SE has announced the date for its Annual General Meeting of shareholders, scheduled for May 27, 2025, in Amsterdam. The meeting will address several recurrent agenda items, including discussions on the 2024 annual accounts and a new remuneration policy. Additionally, shareholders will have the chance to re-appoint directors and vote on key company matters. The formal notice and relevant documents are accessible via the company's website.
Read more →ARGXargenx Announces Annual General Meeting of Shareholders on May 27, 2025
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Read more →ARGXargenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy VYVGART, the first-in-class FcRn blocker, now o
argenx has received FDA approval for the VYVGART Hytrulo prefilled syringe, allowing patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy to self-administer injections. This development aims to enhance treatment independence and flexibility for patients. The approval is based on studies confirming the syringe's bioequivalence to the already approved vial formulation. argenx's commitment to improving patient access and delivery of care is emphasized by the newly available My VYVGART Path support program.
Read more →ARGXargenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP ADAPT-NXT data demonstrate consistent, sustained disease c
argenx showcased significant findings related to its VYVGART treatment at the AAN 2025 Annual Meeting. The data presented emphasizes the medication's sustained efficacy and improved quality of life for patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx reiterated its commitment to address unmet needs in the neuromuscular disease space, alongside advancements in its clinical pipeline, including the new candidate ARGX-119. Overall, the presentations underscore the viability and ongoing impact of VYVGART in patient treatment regimens.
Read more →ARGXargenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting Largest safety data set on FcRn blocking demonstrates consistent, favor
Argenx SE is set to present promising long-term data on its treatments, VYVGART and VYVGART Hytrulo, at the American Academy of Neurology meeting in April 2025. The data highlights the efficacy and safety of VYVGART in improving outcomes for patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The presentations will focus on real-world clinical evidence supporting sustained improvements in patient functionality and symptom reduction. Argenx aims to continue its leadership in FcRn biology and improve treatment approaches for rare autoimmune diseases.
Read more →ARGXargenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Read more →ARGXargenx to Present at TD Cowen 45th Annual Healthcare Conference
argenx has announced its participation in the TD Cowen 45th Annual Healthcare Conference, where CEO Tim Van Hauwermeiren will present on March 3, 2025. This event underscores the company's ongoing commitment to addressing severe autoimmune diseases. Interested parties can access a live webcast of the presentation through the company's investor website, with a replay option available for 30 days post-event.
Read more →ARGXargenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Argentx has announced a conference call and audio webcast scheduled for February 27, 2025, at 2:30 PM CET. The call will focus on the company's financial results for the full year of 2024 and provide updates regarding the fourth quarter. This initiative reflects argentx's continued commitment to transparency with its stakeholders.
Read more →ARGXargenx Highlights 2025 Strategic Priorities
argenx Highlights 2025 Strategic Priorities
Read more →ARGXargenx Highlights 2025 Strategic Priorities Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April
argenx has announced its strategic priorities for 2025, highlighting a strong financial performance with preliminary global product net sales of $2.2 billion for 2024. The company is positioning itself for sustainable profitability, with 10 ongoing registrational studies and a focus on the upcoming FDA approval of its pre-filled syringe. Additionally, argenx aims to expand its market presence with its first-in-class treatments and an ambitious Vision 2030 plan targeting a global patient reach of 50,000. The focus remains on innovation and broadening its pipeline to address autoimmune diseases.
Read more →ARGXargenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy VYVDURA now approved for at-home self-injection in Japan for both
argenx SE announced that Japan's Ministry of Health has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This treatment allows for self-administration at home and is noted as the first FcRn blocker approved for this condition. The approval is supported by clinical evidence from the ADHERE trial, showing a significant improvement in 69% of patients. This marks a significant advancement in therapeutic options for this debilitating disease.
Read more →ARGXargenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - Phase 2 data establish proof-of-concept of efgartigimod SC in myositis - Enrollment to continue in Phase 3 across all three
argenx has announced a continuation of the clinical development of efgartigimod SC for idiopathic inflammatory myopathies, following positive Phase 2 results. The study demonstrated a statistically significant treatment effect in patients with various subtypes of myositis. Enrollment in the ongoing Phase 2/3 ALKIVIA study will proceed, with a total of 240 patients anticipated. Efgartigimod SC may provide a new targeted treatment option for this patient population, which currently has limited therapeutic alternatives.
Read more →ARGXargenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indicat
argenx and Zai Lab have received approval from China's NMPA for VYVGART Hytrulo, the first treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in the country. This therapy, indicated for adult patients, addresses the significant unmet need among the estimated 50,000 diagnosed CIDP patients in China. Supported by positive results from the ADHERE study, VYVGART Hytrulo presents a new, effective option, emphasizing the collaboration between argenx and Zai Lab to improve patient outcomes.
Read more →ARGXargenx to Participate at Upcoming Investor Conferences
argenx to Participate at Upcoming Investor Conferences
Read more →ARGXargenx Reports Third Quarter 2024 Financial Results and Provides Business Update
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Read more →ARGXargenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
Read more →ARGXargenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scie
argenx SE presented encouraging data at the 2024 AANEM and MGFA meetings, showcasing the effectiveness of VYVGART for treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The data highlighted VYVGART's rapid and sustained patient benefits, including reductions in steroid use. Additionally, argenx detailed advancements in its neurology pipeline, particularly with empasiprubart for multifocal motor neuropathy and ARGX-119 for congenital myasthenic syndromes. The safety profile of VYVGART remains favorable with no significant adverse effects reported. Overall, the presentations affirm the promising impact of argenx's therapies on patient health outcomes.
Read more →ARGXargenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGAR
argenx has announced the publication of pivotal data from the ADHERE study in The Lancet Neurology, highlighting the effectiveness of VYVGART Hytrulo in treating chronic inflammatory demyelinating polyneuropathy (CIDP). This study is noted to be the largest clinical trial conducted for CIDP patients. VYVGART Hytrulo has shown a significant reduction in disease progression and relapse risk. The drug is the first FDA-approved neonatal Fc receptor blocker for CIDP, representing an important advancement in the treatment of this debilitating condition.
Read more →ARGXargenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
Read more →ARGXargenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
Read more →ARGXEx * reflects cash, cash equivalents and current financial assets hibit 99.1 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update $478 million in second quarter global net product s
argenx SE reported its financial results for the first half of 2024, showcasing impressive growth with $478 million in global net product sales for the second quarter. The company is progressing with its clinical pipeline, having treated the first CIDP patients with VYVGART following FDA approval. Described as a 'Vision 2030,' argenx outlined its strategic goals aimed at increasing patient access and expanding the number of labeled indications. Despite reporting an operating loss, argenx's financial performance reflects a significant improvement compared to the same period last year.
Read more →ARGXargenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients i
argenx and Zai Lab have received approval from the National Medical Products Administration (NMPA) in China for Efgartigimod Alfa Injection (subcutaneous injection) for the treatment of generalized myasthenia gravis (gMG). This marks the first approved subcutaneous FcRn blocker for gMG, aiming to meet the significant unmet medical needs of approximately 170,000 patients in the region. The therapy demonstrated a favorable clinical benefit and safety profile in clinical trials, compared to its intravenous counterpart. The approval is expected to enhance treatment flexibility for patients, allowing a more individualized approach to management.
Read more →ARGXargenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting ARDA study data show potential for empasiprubart to drive functional improvement
argenx SE recently presented new data at the 2024 Peripheral Nerve Society Annual Meeting, highlighting the company's autoimmune pipeline, particularly focusing on the Phase 2 ARDA study of empasiprubart for multifocal motor neuropathy (MMN). The data indicate that empasiprubart may offer significant functional improvement and risk reduction of relapse for MMN patients. Additionally, argenx showcased promising results from the pivotal ADHERE study regarding VYVGART Hytrulo, an approved treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), evidencing its sustained efficacy and safety. This presentation underlines argenx's objective to innovate therapies that address unmet needs in severe autoimmune diseases.
Read more →ARGXargenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelin
argenx SE has announced the FDA approval of VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), making it the first neonatal Fc receptor blocker approved for this condition. This treatment option aims to improve the quality of life for patients suffering from CIDP, a debilitating immune-mediated disorder. The approval is based on the promising results of the ADHERE trial, which demonstrated significant clinical improvement in a majority of participants. VYVGART Hytrulo is expected to be available to U.S. patients immediately, addressing a critical need for more diverse treatment options in CIDP.
Read more →ARGXargenx to unveil its Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on
Argenx has announced an R&D Day scheduled for July 16, 2024, to present its Vision 2030, which aims to bring breakthrough science to 50,000 patients. They will showcase Phase 2 data supporting the advancement of candidates like efgartigimod and empasiprubart for Sjogren's disease and multifocal motor neuropathy. However, the company has decided not to pursue further development of efgartigimod for post-COVID-19-mediated postural orthostatic tachycardia syndrome due to disappointing clinical trial results. The event will highlight Argenx's commitment to addressing severe autoimmune diseases through an innovative pipeline.
Read more →ARGXargenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Read more →ARGXargenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of
argenx SE reported its first quarter financial results for 2024, highlighting $398 million in net product sales. The company is preparing for an FDA review of its CIDP sBLA, with a target action date set for June 21, 2024. Management announced plans to submit filing for a pre-filled syringe by the second quarter of 2024, indicating ongoing pipeline developments. Although revenues increased, argenx suffered a loss for the period, prompting ongoing discussions of future financial strategies.
Read more →ARGXargenx announces results of Annual General Meeting of Shareholders
argenx SE announced the results of its Annual General Meeting, where all agenda items received majority approval, except for the remuneration policy. The company is focusing on developing antibody-based medicines, notably its approved neonatal Fc receptor blocker. Additionally, argenx is evaluating its product in various autoimmune diseases and promoting several early-stage experimental therapies.
Read more →ARGXargenx to Present at BofA Securities 2024 Health Care Conference
argenx to Present at BofA Securities 2024 Health Care Conference
Read more →ARGXargenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
Read more →ARGXargenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART Hytrulo has potential to be first advancement for C
argenx SE presented new data from its Phase 3 ADHERE trial at the AAN Annual Meeting, highlighting the efficacy of VYVGART and VYVGART Hytrulo for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The trial showed a significant reduction in relapse risk and improved clinical outcomes, with many patients able to reduce their use of steroids. Notably, VYVGART Hytrulo is positioned as a significant advancement in treatment for CIDP after a 30-year gap.
Read more →ARGXargenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across effi
argenx SE has announced the advancement of efgartigimod to Phase 3 clinical trials for adults with primary Sjogren's disease, based on positive topline data from the Phase 2 RHO study. The decision was supported by favorable safety profiles and consistent efficacy across multiple clinical endpoints and biomarker measures. As there are no current approved therapies for this debilitating condition, the move aims to address a significant unmet medical need. Detailed results are expected to be presented at a future medical meeting.
Read more →ARGXargenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia VYVGART now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (
argenx has received approval from Japan's Ministry of Health for VYVGART (efgartigimod alfa) to be used in adults with primary immune thrombocytopenia (ITP). This marks the first global approval of the drug for this condition, expanding its existing indication for generalized myasthenia gravis. The approval is based on results from the Phase 3 ADVANCE-IV trial, which showed that VYVGART significantly improved platelet counts in chronic ITP patients compared to placebo. The drug is particularly noted for its rapid onset of effect and targeted mechanism to reduce autoantibodies responsible for the disease.
Read more →ARGXAnnualReport2023 Disclaimer PDF print – this document is only a “printed version” and is not the original annual financial reporting including the audited financial statements pursuant to Article 361
The document titled 'AnnualReport2023 Disclaimer PDF print' serves as a printed version of the annual financial report for argenx SE. It outlines the company's collaboration agreements, including an exclusive out-license with Zai Lab for the development and commercialization of efgartigimod in Greater China. Additionally, it mentions various financial details such as upfront payments and milestone payments associated with these agreements. The full annual report is available online at the specified URL.
Read more →ARGXargenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting ADHERE data presentation will highlight first potential innovation for CIDP patients in 30
argenx SE announced that it will present eight abstracts at the American Academy of Neurology 2024 Annual Meeting, including oral presentations of VYVGART and VYVGART Hytrulo data. The data showcase the potential of these treatments to provide significant benefits to patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a community that has seen no innovation for three decades. The findings will further detail the efficacy, safety, and long-term use of these therapies. A PDUFA target action date of June 21, 2024, has been set for the potential FDA approval of VYVGART Hytrulo in CIDP.
Read more →ARGXargenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update $374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART Hytrulo for CIDP accepted
argenx SE reported significant financial results for the full year 2023, with global net product sales reaching $1.2 billion. The company is preparing for a pivotal year in 2024, with the FDA's priority review of VYVGART for chronic inflammatory demyelinating polyneuropathy (CIDP) and ongoing Phase 2 trials. Despite a net loss of $295 million for the year, the company has a strong cash position of $3.2 billion to support its expansion and development efforts. Management remains optimistic about leveraging their recent successes to further broaden patient access and enhance their immunology pipeline.
Read more →ARGXargenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
Read more →ARGXargenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy Prescription Drug User Fee Act (PDUFA) target ac
argenx SE announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for VYVGART Hytrulo, granting it priority review. This application aims to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and has a target action date of June 21, 2024. VYVGART Hytrulo is noteworthy as the first neonatal Fc receptor blocker for CIDP, and clinical data from the ADHERE study indicate it has the potential to significantly reduce relapse rates. The medication has demonstrated a well-tolerated safety profile, which is crucial for patient adoption.
Read more →ARGXargenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis Availability of VYVGART and self-administered VYVDURA demonstrates
argenx SE announced the approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in Japan for adult patients with generalized myasthenia gravis (gMG). This approval, granted by the Ministry of Health, Labour and Welfare, provides a new self-administered treatment option for patients who do not adequately respond to existing therapies. It follows promising results from the Phase 3 ADAPT-SC study, which demonstrated the drug's efficacy. With VYVDURA, argenx now offers two treatment formulations in Japan for gMG patients, enhancing their options for managing this chronic autoimmune disease.
Read more →ARGXE xhibit 99.1 argenx Highlights 2024 Strategic Priorities Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART Hytrulo for CIDP with priority review voucher (PRV
argenx SE has reported strong preliminary financial results for 2023, with global net product sales reaching approximately $1.2 billion. The company has submitted a supplemental biologics license application (sBLA) for VYVGART Hytrulo for CIDP to the FDA and is anticipating a launch in mid-2024 if approved. Additionally, argenx has shared promising clinical data from its Phase 2 trial for the drug empasiprubart in multifocal motor neuropathy (MMN), with more trials scheduled for the future. The company aims to enhance its pipeline with four new investigational new drug applications anticipated by the end of 2025.
Read more →ARGXargenx Highlights 2024 Strategic Priorities
argenx Highlights 2024 Strategic Priorities
Read more →ARGXargenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO
argenx SE announced the topline results from its ADDRESS study evaluating efgartigimod SC for treating pemphigus vulgaris and pemphigus foliaceus. The study results revealed no significant difference in primary endpoints compared to placebo, prompting argenx to deprioritize this indication. Despite the disappointing outcomes, the company remains committed to its ongoing severe autoimmune indications and plans to apply learnings from this study to future developments. A conference call is scheduled to discuss the implications of these results further.
Read more →ARGXargenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia - Study did not meet primary or secondary endpoints - Favorable safety and tolerability profile consistent with p
argenx announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo for primary immune thrombocytopenia (ITP), which did not achieve its primary endpoint of sustained platelet count response in chronic ITP patients. The study’s findings represent a setback for argenx in its ongoing efforts to develop treatment options for ITP, although the safety profile has remained favorable. The Company will continue analyzing the data and remains committed to the ITP patient community. Full results will be shared at a future medical meeting and in a peer-reviewed publication.
Read more →ARGXargenx Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis VYVGART is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in
argenx has received approval from the European Commission for its subcutaneous formulation of VYVGART (efgartigimod alfa) to treat generalized myasthenia gravis. This adds to the existing intravenous formulation that was approved in August 2022. The approval is based on positive results from the Phase 3 ADAPT-SC trial and is aimed at providing flexibility for patients through self-administration. This approval is effective across all EU Member States and other associated European countries.
Read more →ARGXargenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions Long-term clinical trial and real-world data illustrate VYVGART drives consistent, repeatable and clinic
argenx SE highlighted positive clinical data for VYVGART in treating neuromuscular autoimmune diseases at AANEM and MGFA sessions. The long-term trial data indicates that VYVGART offers consistent clinical responses and improvement in quality of life for patients with generalized myasthenia gravis (gMG). Safety profiles remain favorable, with no increase in adverse events noted over extended use. The company presented a range of studies, reinforcing its commitment to addressing health disparities in the neuromuscular community.
Read more →ARGXargenx Reports Third Quarter 2023 Financial Results and Provides Business Update - $329 million in third quarter global net product sales - On track to submit VYVGART Hytrulo sBLA for CIDP by year-end 2023 - Results from
argenx SE has reported strong financial results for Q3 2023, with global net product sales reaching $329 million. The company is on track to submit a supplemental Biologics License Application for VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy by the end of the year. argenx plans to broaden its treatment offerings into new geographies and treatment lines. Despite these positive developments, the company reported an operating loss of $80.6 million for the quarter, reflecting ongoing high research and development expenses.
Read more →ARGXargenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
Read more →ARGXargenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval
argenx SE has received authorization from Health Canada for VYVGART (efgartigimod alfa), the first neonatal Fc receptor blocker for treating generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. This regulatory approval follows favorable results from the Phase 3 ADAPT trial, which demonstrated significant efficacy in treating gMG symptoms. VYVGART aims to fulfill a significant medical need for patients suffering from this debilitating autoimmune disease by offering a targeted treatment. This milestone marks an important advancement for the gMG community in Canada, providing new hope for effective management of their condition.
Read more →ARGXargenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Read more →ARGXargenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update - $269 million in second quarter VYVGART (efgartigimod alfa-fcab) global net product sales - VYVGART Hytrulo now available in th
argenx SE reported a strong performance for the first half of 2023, highlighted by $269 million in net product sales from VYVGART in the second quarter. The company announced ambitious plans for expanding treatment options and regulatory approvals, especially after positive clinical data for CIDP. Despite significant growth, the company's operating losses and increasing expenses present ongoing financial challenges. The firm remains committed to developing its innovative product pipeline in the autoimmune disease space.
Read more →ARGXargenx announces closing of global offering
argenx announces closing of global offering
Read more →ARGXargenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
Read more →ARGXargenx announces full exercise of underwriters’ option to purchase additional ADSs
argenx announces full exercise of underwriters’ option to purchase additional ADSs
Read more →ARGXargenx raises $1.1 billion in gross proceeds in a global offering
argenx raises $1.1 billion in gross proceeds in a global offering
Read more →ARGXargenx announces launch of proposed global offering
argenx announces launch of proposed global offering
Read more →ARGXargenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy - Study met primary endpoint (p=0.000039); VYVGART Hytrulo demonstrated 61% red
argenx has announced positive topline results from its ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, showing a significant reduction in the risk of relapse compared to placebo. With a well-tolerated safety profile, these findings suggest VYVGART Hytrulo could be an effective treatment option for CIDP patients, potentially alleviating their symptoms and improving their quality of life. Detailed results are expected to be presented at an upcoming medical meeting.
Read more →ARGXRegulated information - Inside information argenx announces launch of proposed global offering
argenx SE has announced the commencement of a global offering of approximately $750 million in ordinary shares, including American Depository Shares (ADSs). The offering will be split between the U.S. and other countries outside of the European Economic Area, accompanied by a simultaneous private placement in the EEA and the UK. A 30-day option is available for underwriters to purchase additional shares. This offering aims to bolster argenx's investment in its treatments for severe autoimmune diseases.
Read more →ARGXargenx and Zai Lab Announce Approval of VYVGART ( efgartigimod alfa injection) for Generalized Myasthenia Gravis in China First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positiv
argenx and Zai Lab announced the approval of VYVGART (efgartigimod alfa injection) for the treatment of generalized myasthenia gravis (gMG) in China by the National Medical Products Administration (NMPA). VYVGART is the first neonatal Fc receptor antagonist approved for gMG patients, specifically those who are anti-acetylcholine receptor (AChR) antibody positive. This approval represents a crucial step towards improving treatment accessibility and efficacy for over 200,000 gMG patients in China, highlighting a significant unmet medical need. Both companies expressed commitment to expanding treatment options and exploring further indications for efgartigimod.
Read more →ARGXargenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy Independent Data Monitoring Committee recommended study continuation based on the favorable safety profile observed in
argenx has announced the initiation of the second cohort in its Phase 2 ARDA study of empasiprubart for multifocal motor neuropathy (MMN). This follows a favorable interim analysis by the Independent Data Monitoring Committee, affirming the safety and early efficacy of empasiprubart observed in the first cohort. The study aims to build on these promising results while evaluating a new dose level of empasiprubart. Overall, this advancement highlights argenx's commitment to enhancing treatment for patients with this chronic autoimmune disease.
Read more →ARGXargenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Read more →ARGXargenx Reports First Quarter 2023 Financial Results and Provides Business Update - $218 million in first quarter VYVGART (efgartigimod alfa-fcab) global net product sales - VYVGART received marketing authorization in Isr
argenx reported its first quarter 2023 financial results, showcasing considerable growth with $218 million in sales for their product VYVGART. The company has also received marketing authorization for VYVGART in Israel and is progressing in multiple clinical trials, with data expected in the upcoming months. The management highlighted plans to expand the product's use within autoimmune conditions, emphasizing a robust pipeline and ongoing commitment to innovation in the sector.
Read more →ARGXargenx to Present at BofA Securities 2023 Health Care Conference
argenx to Present at BofA Securities 2023 Health Care Conference
Read more →ARGXargenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
Read more →ARGXargenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting Amsterdam, the Netherlands - 04/18/2023 arge
argenx is set to present six abstracts at the 75th American Academy of Neurology Annual Meeting, focusing on the treatment of generalized myasthenia gravis (gMG). Key highlights include clinical data on efgartigimod, which demonstrates its potential to transform treatment for gMG patients. They will also discuss long-term safety profiles and individual dosing strategies. Additionally, argenx is emphasizing patient support initiatives aimed to improve access to treatment, particularly for those facing social challenges.
Read more →ARGXargenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and c
argenx SE and Genmab A/S have announced a multiyear collaboration to jointly discover and develop novel therapeutic antibodies for immunology and oncology. The partnership aims to leverage the strengths of both companies in antibody engineering and disease biology to address unmet patient needs. Initial focus will be on two differentiated disease targets, with potential expansion to more. The agreement includes shared costs and profits from products developed as a result of their collaboration.
Read more →ARGXargenx Announces Annual General Meeting of Shareholders on May 2, 2023
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
Read more →ARGXargenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generali
argenx has received marketing authorization from the UK MHRA for VYVGART, the first neonatal Fc receptor blocker for adults with generalized myasthenia gravis who are anti-AChR antibody positive. Based on the Phase 3 ADAPT trial, VYVGART demonstrated a significant advantage over placebo, with 68% of treated patients achieving positive responses. The company aims to collaborate with local authorities to ensure broad access to this treatment, which offers hope for improved quality of life for affected individuals.
Read more →ARGXargenx Announces Planned Transition of Chief Operating Officer Karen Massey appointed as Chief Operating Officer, effective
argenx has announced the appointment of Karen Massey as the new Chief Operating Officer, effective March 13, 2023. She will replace Keith Woods, who will remain during the transition period before retiring as a strategic advisor. Massey brings over 20 years of experience in the pharmaceutical industry, having previously led product development at Genentech. Her focus will be on building upon argenx's achievements in immunology and furthering the launch of their commercial products.
Read more →ARGXargenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
Read more →ARGXargenx Appoints Steve Krognes to Board of Directors
argenx Appoints Steve Krognes to Board of Directors
Read more →ARGXargenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
Read more →ARGXargenx Announces Extraordinary General Meeting of Shareholders on
argenx SE has scheduled an extraordinary general meeting of shareholders for February 27, 2023, to appoint Steve Krognes as a Non-Executive Director and Chair of the Audit and Compliance Committee. This meeting will take place at the Hilton Amsterdam Schiphol in the Netherlands. The change is part of a long-term succession plan, as current director Werner Lanthaler will resign after eight years with the company. Shareholders are encouraged to use the electronic proxy voting system for participation.
Read more →ARGXargenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
argenx has received notification from the U.S. FDA regarding an extension of the review period for its Biologics License Application for subcutaneous efgartigimod, now set for June 20, 2023. This extension was prompted by a major amendment related to the ongoing review process. Importantly, the FDA has not requested any additional data or studies at this time. The company remains optimistic about efgartigimod's profile and its potential to treat generalized myasthenia gravis.
Read more →ARGXargenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
Read more →ARGXargenx Highlights 2023 Strategic Priorities Across Immunology Pipeline Reported $402 million in preliminary* full-year 2022 global net VYVGART sales ADHERE topline results now expected in second quarter of 2023; Stage B
argenx announced its strategic priorities for 2023 alongside preliminary financial results for the full year 2022, reporting $402 million in global net sales of its product VYVGART. The company aims to expand patient access to VYVGART and start new clinical trials for efgartigimod and other therapies targeting autoimmune diseases. Additionally, argenx plans to submit for marketing approval in Japan for immune thrombocytopenia (ITP) and has a substantial cash reserve that supports its strategy for growth and innovation. The company projects reaching profitability with planned operational activities in the coming years.
Read more →ARGXargenx to Present at 41st Annual J.P. Morgan Healthcare Conference
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Appoints Ana Cespedes to Board of Directors
argenx Appoints Ana Cespedes to Board of Directors
Read more →ARGXargenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
Read more →ARGXargenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia First immune thrombocytopenia (ITP) pl
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rar
Read more →ARGXargenx Enters Into Agreement To Acquire Priority Review Voucher Amsterdam, the Netherlands
argenx Enters Into Agreement To Acquire Priority Amsterdam, the Netherlands - November 30, 2022 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement
Read more →ARGXargenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review - Prescription Drug User Fee Act (PDUFA) target action date is
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review - Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from
Read more →ARGXargenx announces Extraordinary General Meeting of Shareholders on December 12, 2022
argenx announces Extraordinary General Meeting of Shareholders on December 12, 2022
Read more →ARGXargenx Reports Third Quarter 2022 Financial Results and Provides Business Update - $131 million in third quarter VYVGART (efgartigimod alfa-fcab) global net product sales - Filed Biologics License Application (BLA) for s
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update million in third quarter VYVGART (efgartigimod alfa-fcab) global net product sales Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized myasthenia gr
Read more →ARGXargenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
Read more →ARGXargenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis Submission package based on positive data from the Phase 3 AD
Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Netherlands - September 21, 2022 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peopl
Read more →ARGXargenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
Read more →ARGXargenx Appoints Camilla Sylvest to Board of Directors
argenx Appoints Camilla Sylvest to Board of Directors Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary gener
Read more →ARGXargenx to Present at Wells Fargo Healthcare Conference
argenx to Present at Wells Fargo Healthcare Conference
Read more →ARGXargenx Announces European Commission Approval of VYVGART (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the tre
argenx Announces European Commission Approval of VYVGART (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravi
Read more →ARGXargenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update - $75 million in second quarter VYVGART (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch;
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update Breda, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou
Read more →ARGXargenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an extraordinary general meeting of shareholders will be held at 18:30 PM CEST on T
Read more →ARGXargenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
Read more →ARGXargenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinical
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe Breda, the Netherlands-June 24, 2022-argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people
Read more →ARGXargenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Read more →ARGXargenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases - Translational data from Phase 2 study of efgartigimod in pemphigus further demonstrate argenx's scientific leade
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases Breda, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise
Read more →ARGXargenx Reports First Quarter 2022 Financial Results and Provides Business Update - $21.2 million in VYVGART (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launch - Met primary endpoi
argenx Reports First Quarter 2022 Financial Results and Provides Business Update million in VYVGART (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launch primary endpoint in Phase 3 ADVANCE trial of VYVGART for treatment of primary immune
Read more →ARGXargenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Read more →ARGXargenx to Present at BofA Securities 2022 Healthcare Conference
argenx to Present at BofA Securities 2022 Healthcare Conference
Read more →ARGXargenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
Read more →ARGXargenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
Read more →ARGXargenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
Read more →ARGXargenx announces Annual General Meeting of Shareholders on May 10, 2022
argenx announces Annual General Meeting of Shareholders on May 10, 2022
Read more →ARGXargenx raises $700 million in gross proceeds in a global offering
argenx raises $700 million in gross proceeds in a global offering
Read more →ARGXargenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis - Study met primary endpoint, demonstrating noninferior total IgG reduction at day
argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis Regulated Information/Inside Information Breda, the Netherlands - March 22, 2022 - argenx SE (Euronext & Nasdaq: ARGX), a global immunolog
Read more →ARGXargenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update - VYVGART (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial results from Phase 3 bridging study of subcutaneous (S
Read more →ARGXargenx to Present at the 42nd Annual Cowen Health Care Conference
argenx to Present at the 42nd Annual Cowen Health Care Conference
Read more →ARGXargenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
Read more →ARGXargenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Read more →ARGXargenx announces VYVGART approval in Japan for the treatment of generalized myasthenia gravis VYVGART TM (efgartigimod alfa) is the first-and-only FcRn blocker approved in Japan Ministry of Health, Labour and Welfare (MH
argenx announces VYVGART approval in Japan for the treatment of generalized myasthenia gravis Regulated Information/Inside Breda, the Netherlands - Jan. 20, 2022 - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suff
Read more →ARGXTogether We Discover J.P. Morgan Healthcare Conference
Bloemenkamp, Jeroen W. Bos, Marc D. Jansen, Chantall A.D. Curial, Karen Silence, Hans de Haard, Christophe Blanchetot, Liesbeth Van de Ven, Jeanette H.W. Leusen, R. Jeroen Pasterkamp, Leonard H. van den Berg, C. Erik Hack, Peter Boross, W. Ludo van der Pol Neurol Neuroimmunol Neu
Read more →ARGXargenx Highlights Strategic Priorities for 2022 Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new
argenx Highlights Strategic Priorities for 2022 Initiated global VYVGART (efgartigimod alfa-fcab) commercial launch Expect data from five registrational trials of efgartigimod by first quarter of 2023 Announcing four new efgartigimod indications to be initiated in 2022: mem
Read more →ARGXargenx Highlights Strategic Priorities for 2022
argenx Highlights Strategic Priorities for 2022
Read more →ARGXargenx to Present at 40th Annual J.P. Morgan Healthcare Conference
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART Ô (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% o
Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis is the first-and-only FDA-approved neonatal Fc receptor blocker of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYV
Read more →ARGXargenx Reports Third Quarter 2021 Financial Results and Provides Business Update
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
Read more →ARGXargenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
Read more →ARGXargenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
Read more →ARGXargenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Read more →ARGXargenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
Read more →ARGXargenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update Breda, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, tod
Read more →ARGXargenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
Read more →ARGXargenx to Host Virtual R&D Day on July 20, 2021
argenx to Host Virtual R&D Day on July 20, 2021
Read more →ARGXargenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Read more →ARGXargenx to regain global rights to cusatuzumab
argenx to regain global rights to cusatuzumab the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced it will regain worldwide rights to i
Read more →ARGXargenx Appoints Karl Gubitz as Chief Financial Officer
Appoints Karl Gubitz as Chief Financial Officer the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the appointment of Mr. Karl Gubitz as
Read more →ARGXSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-38097 (Translation of registrant's name into English
Read more →ARGXargenx Reports First Quarter 2021 Financial Results and Provides Business Update
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
Read more →ARGXargenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
Read more →ARGXargenx Management to Present at Upcoming Virtual Investor Conferences
argenx Management to Present at Upcoming Virtual Investor Conferences
Read more →ARGXargenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
Read more →ARGXargenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
Read more →ARGXargenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
Read more →ARGXargenx raises $1.0 billion in gross proceeds in a global offering
argenx raises $1.0 billion in gross proceeds in a global offering
Read more →ARGXargenx Issues Statement Concerning Efgartigimod
argenx Issues Statement Concerning Efgartigimod
Read more →ARGXargenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
Read more →ARGXargenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in genera
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline Breda, the Netherlands - Jan. 8, 2021 - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoi
Read more →ARGXargenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potent
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Za
Read more →ARGXargenx to Present at 39th Annual J.P. Morgan Healthcare Conference
argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Enters Into Agreement To Acquire Priority Review Voucher
argenx Enters Into Agreement To Acquire Priority Review Voucher Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that th
Read more →ARGXargenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
Read more →ARGXargenx to Participate in Upcoming Virtual Investor Conferences
argenx to Participate in Upcoming Virtual Investor Conferences
Read more →ARGXargenx Reports Third Quarter 2020 Financial Results and Provides Business Update - Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Dru
argenx Reports Third Quarter 2020 Financial Results and Provides Business Update - Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) - Global Phase 3 ADDRESS trial ev
Read more →ARGXargenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
Read more →ARGXargenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
Read more →ARGXargenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session - New data consistent with positive topline results showing rapid and cl
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session - New data consistent with positive topline results showing rapid and clinically meaningful responses to efgartigimod and safety
Read more →ARGXargenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings
argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings
Read more →ARGXargenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Read more →ARGXargenx reports half year 2020 financial results and provides second quarter business update Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug A
argenx reports half year 2020 financial results and provides second quarter business update Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease
Read more →ARGXargenx to report half year 2020 financial results and second quarter business update on July 30, 2020
argenx to report half year 2020 financial results and second quarter business update on July 30, 2020
Read more →ARGXargenx to Present at Goldman Sachs 41st Annual Global Healthcare Conference
argenx to Present at Goldman Sachs 41st Annual Global Healthcare Conference
Read more →ARGXargenx raises $750 million in gross proceeds in a global offering
argenx raises $750 million in gross proceeds in a global offering
Read more →ARGXargenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
Regulated information – Inside information Trial met primary endpoint (p ˂0.0001) Well-tolerated; safety profile comparable to placebo Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020 Conference call scheduled for toda
Read more →ARGXargenx Announces Positive Topline Phase 3 ADAPT Trial Results
argenx Announces Positive Topline Phase 3 ADAPT Trial Results
Read more →ARGXargenx reports first quarter 2020 financial results and provides business update - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics Licens
argenx reports first quarter 2020 financial results and provides business update - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by - Enrollment paused in ongoing
Read more →ARGXargenx to report first quarter 2020 financial results and business update on May 14, 2020
argenx to report first quarter 2020 financial results and business update on May 14, 2020
Read more →ARGXargenx to Present at BofA Securities Virtual Health Care Conference 2020
argenx to Present at BofA Securities Virtual Health Care Conference 2020
Read more →ARGXargenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
Read more →ARGXargenx reports full year 2019 financial results and provides fourth quarter business update - Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020 - Continued progress across broadest FcRn an
argenx reports full year 2019 financial results and provides fourth quarter business update - Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020 - Continued progress across broadest FcRn antagonist pipeline with up to five Phase 3 trials to be on
Read more →ARGXargenx full year 2019 financial results
argenx full year 2019 financial results
Read more →ARGXargenx to Present at Cowen 40th Annual Health Care Conference
argenx to Present at Cowen 40th Annual Health Care Conference
Read more →ARGXargenx to report full year 2019 financial results and fourth quarter business update on February 27, 2020
argenx to report full year 2019 financial results and fourth quarter business update on February 27, 2020
Read more →ARGXJP Morgan Healthcare Conference January 2020 San Francisco Forward-Looking Statements THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE ( ARGENX OR THE COMPANY ) FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPO
JP Morgan Healthcare Conference January 2020 San Francisco Forward-Looking Statements THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE ( ARGENX OR THE COMPANY ) FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS PRESENTATION IS, OR SHOULD BE
Read more →ARGXargenx Provides Strategic Outlook Advancing Late-Stage Pipeline Towards argenx 2021 Vision Enrollment complete in Phase 3 ADAPT trial of efgartigimod in gMG; topline data expected mid-2020 Positive Phase 2 data of efgart
argenx Provides Strategic Outlook Advancing Late-Stage Pipeline Towards argenx 2021 Vision Enrollment complete in Phase 3 ADAPT trial of efgartigimod in gMG; topline data expected mid-2020 Positive Phase 2 data of efgartigimod in PV support advancement to registrational trial;
Read more →ARGXargenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
Read more →ARGXargenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting argenx to receive
argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting argenx to receive $25 million from Janssen for achievement of enrollment mil
Read more →ARGXargenx Announces Upcoming Investor Events
argenx Announces Upcoming Investor Events
Read more →ARGXargenx announces results of Extraordinary General Meeting of Shareholders
argenx announces results of Extraordinary General Meeting of Shareholders
Read more →ARGXargenx raises $484 million in gross proceeds in a global offering
argenx raises $484 million in gross proceeds in a global offering
Read more →ARGXargenx to Present Data at Upcoming 61st American Society of Hematology (ASH) Annual Meeting
argenx to Present Data at Upcoming 61st American Society of Hematology (ASH) Annual Meeting Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for
Read more →ARGXRegulated information Inside information argenx announces launch of proposed global offering
Regulated information Inside information argenx announces launch of proposed global offering Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies fo
Read more →ARGXargenx to Participate in Upcoming Investor Conferences
argenx to Participate in Upcoming Investor Conferences
Read more →ARGXargenx reports third quarter 2019 financial results and provides business update Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20 Two efgartigimod trial in
argenx reports third quarter 2019 financial results and provides business update Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20 Two efgartigimod trial initiations expected in 4Q19: Phase 2 proof-of-concept trial
Read more →ARGXInvitation to the extraordinary shareholders meeting
Invitation to the extraordinary shareholders meeting Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer,
Read more →ARGXargenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
Read more →ARGXargenx to Present at 2019 Wedbush PacGrow Healthcare Conference
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference
Read more →ARGXargenx reports half year 2019 financial results and second quarter business update · Enrollment on track for Phase 3 ADAPT trial of efgartigimod (ARGX-113) in generalized myasthenia gravis (gMG) patients with toplin
argenx reports half year 2019 financial results and second quarter business update Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for
Read more →ARGXargenx to report half year 2019 financial results and second quarter business update on August 1, 2019
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
Read more →ARGXargenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology May 28 , 2019 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology com
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapi
Read more →ARGXargenx announces pipeline expansion and argenx 2021 vision to build integrated immunology company at 2019 R&D Day Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Progra
argenx announces pipeline expansion and argenx 2021 vision to build integrated immunology company at 2019 R&D Day Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation
Read more →ARGXargenx to Host R&D Day on May 22, 2019
argenx to Host R&D Day on May 22, 2019
Read more →ARGXargenx reports first quarter 2019 financial results and provides business update
argenx reports first quarter 2019 financial results and provides business update Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
Read more →ARGXargenx to Present at Bank of America Merrill Lynch 2019 Health Care Conference
argenx to Present at Bank of America Merrill Lynch 2019 Health Care Conference
Read more →ARGXargenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie - Initiation of first-in-human clinical trial with antibody product candidate ABBV-151 (ARGX-115)
argenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie - Initiation of first-in-human clinical trial with antibody product candidate ABBV-151 (ARGX-115) Breda, the Netherlands/Ghent, Belgium argenx (Euronext & Nas
Read more →ARGXargenx to Present at Cowen and Company 39th Annual Health Care Conference
argenx to Present at Cowen and Company 39th Annual Health Care Conference
Read more →ARGXargenx reports fourth quarter business update and full year 2018 financial results
argenx reports fourth quarter business update and full year 2018 financial results Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
Read more →ARGXargenx to host conference call & webcast to report fourth quarter business update and full year 2018 financial results on February 28, 2019
argenx to host conference call & webcast to report fourth quarter business update and full year 2018 financial results on February 28, 2019
Read more →ARGXargenx and Halozyme enter global collaboration and license agreement for ENHANZE technology argenx gains access to ENHANZE subcutaneous delivery technology for up to three targets, including exclusive rights to develop t
argenx and Halozyme enter global collaboration and license agreement for ENHANZE technology argenx gains access to ENHANZE subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor Fc
Read more →ARGXargenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen $200 million equity investment made by Johnson & Johnson Innovation
argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen $200 million equity investment made by Johnson & Johnson Innovation JJDC, Inc. Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a cl
Read more →ARGXargenx to Present at 37th Annual J.P. Morgan Healthcare Conference
argenx to Present at 37th Annual J.P. Morgan Healthcare Conference
Read more →ARGXargenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia - Detailed Phase 2 ITP data show clear correlatio
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia -Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reducti
Read more →ARGXRegulated information — Inside information argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) · Collaboration
Regulated information — Inside information argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: A
Read more →ARGXargenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
Read more →ARGXRegulated information Inside information argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60 th American Society of Hematology Annual Meeting and Exposition - 92% overall res
Regulated information Inside information argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition - 92% overall response rate with durability up to 14.4 months in ongoing an
Read more →ARGXargenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition
Read more →ARGXargenx reports third quarter 2018 financial results and provides business update
argenx reports third quarter 2018 financial results and provides business update Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the trea
Read more →ARGXargenx awarded 2.6 million VLAIO grant to explore new applications of ABDEG technology
argenx awarded 2.6 million VLAIO grant to explore new applications of ABDEG technology Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the tr
Read more →ARGXargenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million
Accessibility: Skip TopNav argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million September 21, 2018 16:00 ET Regulated information September 21, 2018, 4:00 PM ET - 10:00 PM CEST Breda, the Netherlands / Ghent, Belgium - argenx (E
Read more →ARGXargenx announces closing of U.S. public offering
argenx announces closing of U.S. public offering
Read more →ARGXargenx raises approximately $300.6 million in gross proceeds in a U.S. public offering
argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering
Read more →ARGXRegulated information Inside information argenx announces launch of proposed public offering in the United States
Regulated information Inside information argenx announces launch of proposed public offering in the United States September 17, 2018, 10:00 PM CEST 4:00 PM ET Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company develo
Read more →ARGXargenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia Favorable safety and tolerability consistent with efgartigimod clinical trials to date Clinic
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia Favorable safety and tolerability consistent with efgartigimod clinical trials to date Clinically meaningful platelet count improvements showed clear s
Read more →ARGXargenx announces launch of proposed public offering in the United States
argenx announces launch of proposed public offering in the United States
Read more →ARGXargenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of diff
Read more →ARGXargenx receives feedback from Japan s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis
argenx receives feedback from Japan s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeli
Read more →ARGXargenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody Breda, the Netherlands/Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antib
Read more →ARGXargenx to Present at 2018 Wedbush PacGrow Healthcare Conference
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
Read more →ARGXargenx reports second quarter business update and half-year 2018 financial results Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT
argenx reports second quarter business update and half-year 2018 financial results Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company deve
Read more →ARGXargenx to host conference call & webcast to report second quarter business update
argenx to host conference call & webcast to report second quarter business update
Read more →ARGXargenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of diff
Read more →ARGXargenx receives milestone payment from strategic collaboration with Shire
argenx receives milestone payment from strategic collaboration with Shire Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of s
Read more →ARGXargenx receives second preclinical milestone payment under its development agreement with AbbVie
argenx receives second preclinical milestone payment under its development agreement with AbbVie Breda, the Netherlands/Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies
Read more →ARGXargenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris Rapid disease control observed in 4/6 patients Strong PD effect correlates
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris Rapid disease control observed in 4/6 patients Strong PD effect correlates with improvement in PDAI score Favorable tolerability pro
Read more →ARGXargenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation - Subcutaneous formulation offers potential for increased p
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation - Subcutaneous formulation offers potential for increased patient convenience and acceptance - Breda, the Netherlan
Read more →ARGXargenx to host KOL breakfast symposium on immune thrombocytopenia
argenx to host KOL breakfast symposium on immune thrombocytopenia
Read more →ARGXargenx selected for BEL 20 Index
argenx selected for BEL 20 Index Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, tod
Read more →ARGXargenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
Read more →ARGXargenx reports first quarter 2018 financial results and provides business update
argenx reports first quarter 2018 financial results and provides business update
Read more →ARGXargenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting Eight-week follow-up data show sep
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting Eight-week follow-up data show separation of clinical efficacy scores between treatment gro
Read more →ARGXargenx to receive third preclinical milestone payment from collaboration with LEO Pharma Milestone associated with CTA approval for ARGX-112
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma Milestone associated with CTA approval for ARGX-112 Breda, the Netherlands/Ghent, Belgium argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline
Read more →ARGXargenx appoints Keith Woods as Chief Operating Officer
argenx appoints Keith Woods as Chief Operating Officer Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune di
Read more →ARGXargenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
Read more →ARGXargenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based th
Read more →ARGXargenx announces Annual General Meeting of Shareholders on May 8, 2018
argenx announces Annual General Meeting of Shareholders on May 8, 2018
Read more →ARGXargenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases Potential for ARGX-117 to have synergistic effect with lead autoimmune compound ARGX-11
argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases Potential for ARGX-117 to have synergistic effect with lead autoimmune compound ARGX-113 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext
Read more →ARGXargenx awarded 2.5 million VLAIO grant to identify novel therapeutic antibodies Grant to fund research of novel targets involved in regulation of locally-released TGF- , a protein active in immunosuppression
argenx awarded 2.5 million VLAIO grant to identify novel therapeutic antibodies Grant to fund research of novel targets involved in regulation of locally-released TGF- , a protein active in immunosuppression Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: AR
Read more →ARGXargenx to Present at Cowen & Company 38th Annual Health Care Conference
argenx to Present at Cowen & Company 38th Annual Health Care Conference
Read more →ARGXargenx reports fourth quarter business update and full year 2017 financial results Management to host conference call today at 3 pm CET / 9 am EST
argenx reports fourth quarter business update and full year 2017 financial results Management to host conference call today at 3 pm CET / 9 am EST Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep
Read more →ARGXargenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
Read more →ARGXargenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
Read more →ARGXargenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
Read more →ARGXargenx announces size of proposed public offering in the United States updated to 3.5 million ADSs
argenx announces size of proposed public offering in the United States updated to 3.5 million ADSs
Read more →ARGXargenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resul
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during t
Read more →ARGXargenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
Read more →ARGXargenx announces results of extraordinary shareholders meeting 2017
argenx announces results of extraordinary shareholders meeting 2017 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe
Read more →ARGXargenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017
argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017
Read more →ARGXargenx launches Phase I trial with subcutaneous formulation of ARGX-113 - Subcutaneous formulation intended for chronic therapy setting
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 - Subcutaneous formulation intended for chronic therapy setting - Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline
Read more →ARGXargenx reports third quarter 2017 financial results and provides business update
argenx reports third quarter 2017 financial results and provides business update Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for t
Read more →ARGXargenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris - Interim data expected in H2 2018
argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris - Interim data expected in H2 2018 - Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep p
Read more →ARGXNon-regulated information argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
Non-regulated information argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated a
Read more →ARGXargenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
Read more →ARGXargenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia - Top-line data from the study expected in second half of 2018
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia - Top-line data from the study expected in second half of 2018 - Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company deve
Read more →ARGXargenx reports second quarter business update and half-year 2017 financial results Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT
argenx reports second quarter business update and half-year 2017 financial results Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a
Read more →ARGXargenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE Antibody TM ARGX-116 for the treatment of dyslipidemia -anti-ApoC3 antibody developed as part of research
argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia -anti-ApoC3 antibody developed as part of research collaboration with Staten Biotechnology- - Stems from arge
Read more →ARGXargenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017
argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017
Read more →ARGXargenx to present at Wedbush PacGrow Healthcare Conference
argenx to present at Wedbush PacGrow Healthcare Conference
Read more →ARGXargenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)
argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore) Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company devel
Read more →ARGXargenx receives second preclinical milestone payment in collaboration with LEO Pharma
argenx receives second preclinical milestone payment in collaboration with LEO Pharma Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the tr
Read more →ARGXargenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML)
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML) Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology
Read more →ARGXargenx to Present at JMP Securities Life Sciences Conference
argenx to Present at JMP Securities Life Sciences Conference
Read more →ARGXargenx announces closing of NASDAQ IPO
argenx announces closing of NASDAQ IPO
Read more →ARGXargenx raises approximately $100 million gross proceeds with NASDAQ IPO
Accessibility: Skip TopNav argenx raises approximately $100 million gross proceeds with NASDAQ IPO May 17, 2017 21:57 ET Regulated information - inside information Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX, Nasdaq: ARGX), a clinical-stage biote
Read more →ARGXRegulated information inside information argenx announces full exercise of underwriters option to purchase additional ADSs 19 May 2017 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX) announced to
Regulated information inside information argenx announces full exercise of underwriters option to purchase additional ADSs Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX) announced today that the underwriters of its initial public offering in the United
Read more →ARGXargenx announces size of initial public offering in the United States increased to 5 million ADSs
argenx announces size of initial public offering in the United States increased to 5 million ADSs
Read more →ARGXargenx announces launch of proposed initial public offering in the United States
argenx announces launch of proposed initial public offering in the United States
Read more →ARGXargenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
Read more →ARGXargenx reports first quarter 2017 financial results and provides business update
argenx reports first quarter 2017 financial results and provides business update
Read more →ARGXargenx announces results of Annual General Meeting 2017
argenx announces results of Annual General Meeting 2017
Read more →ARGXargenx files registration statement for a proposed public offering in the United States
argenx files registration statement for a proposed public offering in the United States
Read more →ARGXargenx receives first preclinical milestone payment in AbbVie collaboration
argenx receives first preclinical milestone payment in AbbVie collaboration
Read more →ARGXargenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients
Read more →ARGXargenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
Read more →ARGXargenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
Read more →ARGXargenx reports fourth quarter business update and full year 2016 financial results
argenx reports fourth quarter business update and full year 2016 financial results
Read more →ARGXargenx announces Annual General Meeting of Shareholders 26 April 2017
argenx announces Annual General Meeting of Shareholders 26 April 2017
Read more →ARGXargenx to host conference call & webcast to report fourth quarter business update and full year 2016 financial results on March 15, 2017
argenx to host conference call & webcast to report fourth quarter business update and full year 2016 financial results on March 15, 2017
Read more →ARGXargenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
Accessibility: Skip TopNav argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia March 06, 2017 01:00 ET -Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia- - Represents latest collabo
Read more →ARGXargenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
Read more →ARGXargenx to Present at Cowen & Co 37th Annual Health Care conference
Accessibility: Skip TopNav argenx to Present at Cowen & Co 37th Annual Health Care conference February 28, 2017 01:00 ET Breda, the Netherlands / Ghent, Belgium- argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiat
Read more →ARGXargenx announces intention to conduct a registered public offering in the United States
argenx announces intention to conduct a registered public offering in the United States
Read more →ARGXargenx announces extension of therapeutic antibody alliance with Shire
Accessibility: Skip TopNav argenx announces extension of therapeutic antibody alliance with Shire February 27, 2017 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differe
Read more →ARGXargenx to Present at Cowen & Co 37th Annual Healthcare conference
argenx to Present at Cowen & Co 37th Annual Healthcare conference
Read more →ARGXargenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
Read more →ARGXargenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
Accessibility: Skip TopNav argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis January 09, 2017 01:00 ET - Topline data from the study expected in second half of 2018 - Breda, the Netherlands / Ghent, Belgium - argenx (Euronext B
Read more →ARGXargenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine
Accessibility: Skip TopNav argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine December 29, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Bru
Read more →ARGXargenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
Accessibility: Skip TopNav argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients December 15, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical com
Read more →ARGXargenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
Read more →ARGXargenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting
Accessibility: Skip TopNav argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting December 02, 2016 01:00 ET Workshop to occur on Sunday December 4th at 11:00 am PT Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Bru
Read more →ARGXargenx Reports Third Quarter 2016 Financial Results and Provides Business Update
Accessibility: Skip TopNav argenx Reports Third Quarter 2016 Financial Results and Provides Business Update October 27, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and
Read more →ARGXargenx Reports Third Quarter 2016 Financial Results and Provides Business Update
argenx Reports Third Quarter 2016 Financial Results and Provides Business Update
Read more →ARGXFrost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™
Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™
Read more →ARGXargenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York
Read more →ARGXargenx to host inaugural R&D day and webcast on September 22, 2016
Accessibility: Skip TopNav argenx to host inaugural R&D day and webcast on September 22, 2016 September 15, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium, 15 September 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creati
Read more →ARGXargenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
Accessibility: Skip TopNav argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results August 26, 2016 01:00 ET Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers Phase 2 study in first auto-immune indication planne
Read more →ARGXargenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
Read more →ARGXargenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016
Accessibility: Skip TopNav argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016 August 19, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clin
Read more →ARGXargenx to Present at Wedbush PacGrow Healthcare Conference
Accessibility: Skip TopNav argenx to Present at Wedbush PacGrow Healthcare Conference August 10, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differe
Read more →ARGXargenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016
argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016
Read more →ARGXargenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
Accessibility: Skip TopNav argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers June 30, 2016 01:00 ET Data show potent reduction of IgG levels of up to 85% and a favorable safety and tolerability profile Phase 2
Read more →ARGXargenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
Read more →ARGXargenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
Accessibility: Skip TopNav argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016 June 10, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and de
Read more →ARGXargenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
Read more →ARGXargenx successfully closes €30 million private placement
Accessibility: Skip TopNav argenx successfully closes €30 million private placement June 03, 2016 01:00 ET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTIO
Read more →ARGXargenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
Accessibility: Skip TopNav argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111 June 03, 2016 01:00 ET Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment Breda, the Netherlands/Ghent, Belgium - argenx (Eu
Read more →ARGXargenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
Read more →ARGXargenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors
argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors
Read more →ARGXargenx Reports First Quarter 2016 Financial Results and Provides Business Update
Accessibility: Skip TopNav argenx Reports First Quarter 2016 Financial Results and Provides Business Update May 11, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium, 11 May 2016 - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on
Read more →ARGXargenx reports first quarter 2016 financial results and provides business update
argenx reports first quarter 2016 financial results and provides business update
Read more →ARGXargenx announces results of Annual General Meeting 2016
argenx announces results of Annual General Meeting 2016
Read more →ARGXargenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target
Accessibility: Skip TopNav argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target April 21, 2016 01:00 ET --argenx Management to Discuss Collaboration on Conference Call Today at 6 pm CET / noon EDT-- BREDA, THE NETHERLANDS/GHENT, BELGIUM and NORTH
Read more →ARGXargenx's Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody(TM) Against IL-6 to Treat Rheumatoid Arthritis
Accessibility: Skip TopNav argenx's Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody(TM) Against IL-6 to Treat Rheumatoid Arthritis March 16, 2016 03:00 ET Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a
Read more →ARGXargenx announces Annual General Meeting of Shareholders 28 April 2016
argenx announces Annual General Meeting of Shareholders 28 April 2016
Read more →ARGXargenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
Read more →ARGXargenx reports fourth quarter business update and full year 2015 financial results
Accessibility: Skip TopNav argenx reports fourth quarter business update and full year 2015 financial results March 11, 2016 01:00 ET Clinical programs in severe auto-immune diseases and oncology supported by strong financial position Management to host conference call today
Read more →ARGXargenx reports fourth quarter business update and full year 2015 financial results
argenx reports fourth quarter business update and full year 2015 financial results
Read more →ARGXargenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016
Accessibility: Skip TopNav argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016 March 03, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium, 3 March 2016 - argenx (Euronext Brussels: ARGX),
Read more →ARGXargenx: Home Member State Selection
Accessibility: Skip TopNav argenx: Home Member State Selection February 26, 2016 01:00 ET Breda, the Netherlands/Ghent, Belgium, 26 Fabruary 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated th
Read more →ARGXargenx opens clinical trial sites in South Korea for ARGX-111 program
Accessibility: Skip TopNav argenx opens clinical trial sites in South Korea for ARGX-111 program February 18, 2016 01:00 ET Breda, the Netherlands/Ghent, Belgium, 18 Febr 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating an
Read more →ARGXargenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference
Accessibility: Skip TopNav argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference February 05, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium, 5 February 2016- argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focuse
Read more →ARGXargenx receives milestone payment in LEO Pharma collaboration
Accessibility: Skip TopNav argenx receives milestone payment in LEO Pharma collaboration February 02, 2016 01:00 ET Breda, the Netherlands / Ghent, Belgium, 2 February 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and d
Read more →ARGXargenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors
argenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors
Read more →ARGXargenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors
argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors
Read more →ARGXargenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers
Accessibility: Skip TopNav argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers January 06, 2016 01:00 ET Favourable safety and tolerability profile observed Rapid reduction of IgG levels Breda, the Netherlands / Ghent
Read more →ARGXargenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers
argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers
Read more →ARGXargenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program
Accessibility: Skip TopNav argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program December 07, 2015 01:00 ET Workshop and webcast to occur at 12:00 pm ET today Breda, the Netherlands / Ghent, Belgium, 7 December
Read more →ARGXargenx reports third quarter 2015 financial results and provides business update
argenx reports third quarter 2015 financial results and provides business update
Read more →ARGXargenx to Present at Key Investor Conferences
argenx to Present at Key Investor Conferences
Read more →ARGXarGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders
arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders
Read more →ARGXarGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6
arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6
Read more →ARGXarGEN-X Announces Half-Year Results For 2015
arGEN-X Announces Half-Year Results For 2015
Read more →ARGXarGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015
arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015
Read more →ARGXarGEN-X to Present at Wedbush PacGrow Healthcare Conference
arGEN-X to Present at Wedbush PacGrow Healthcare Conference
Read more →ARGXarGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
Read more →ARGXChange to the Board of Directors
Change to the Board of Directors
Read more →ARGXPreliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML
Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML
Read more →ARGXarGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT
arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT
Read more →ARGXarGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO
arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO
Read more →ARGXarGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions
Read more →ARGXarGEN-X Awarded €1.5 Million IWT Grant to Advance the Application of NHance® Fc Modifications in Therapeutic Antibodies
arGEN-X Awarded €1.5 Million IWT Grant to Advance the Application of NHance® Fc Modifications in Therapeutic Antibodies
Read more →ARGXarGEN-X – First Quarter 2015 Financial Results and Business Update
arGEN-X – First Quarter 2015 Financial Results and Business Update
Read more →ARGXarGEN-X Announces Results of Annual General Meeting 2015
arGEN-X Announces Results of Annual General Meeting 2015
Read more →ARGXarGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy
arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy
Read more →ARGXarGEN-x N.V. Announces Changes to the Board of Directors
arGEN-x N.V. Announces Changes to the Board of Directors
Read more →ARGXarGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers
arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111 in Patients with MET Amplified Cancers
Read more →ARGXarGEN-X Announces Annual General Meeting of Shareholders 13 May 2015
arGEN-X Announces Annual General Meeting of Shareholders 13 May 2015
Read more →ARGXarGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results
arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results
Read more →ARGXarGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
Read more →ARGXarGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015
arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015
Read more →ARGXarGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy
arGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy
Read more →ARGXarGEN-X Presents ARGX-111 at Targeted Anticancer Therapies
arGEN-X Presents ARGX-111 at Targeted Anticancer Therapies
Read more →ARGXLonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies
Lonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies
Read more →ARGXarGEN-X Launches Innovative Access Program
arGEN-X Launches Innovative Access Program
Read more →ARGXarGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire
arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire
Read more →ARGXarGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model
Read more →ARGXarGEN-X – Third Quarter Business Update
arGEN-X – Third Quarter Business Update
Read more →ARGXarGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas
arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas
Read more →ARGXarGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia
arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia
Read more →ARGXarGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110
Read more →ARGXarGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b Expansion Trial with ARGX-110
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b Expansion Trial with ARGX-110
Read more →ARGXarGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States
arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States
Read more →ARGXarGEN-X Appoints Petercam NV as Liquidity Provider to Facilitate Trading on Euronext Brussels
arGEN-X Appoints Petercam NV as Liquidity Provider to Facilitate Trading on Euronext Brussels
Read more →ARGXarGEN-X – Business Update and First Half 2014 Results
arGEN-X – Business Update and First Half 2014 Results
Read more →ARGXarGEN-X Announces Positive Preclinical Results for ARGX-113
arGEN-X Announces Positive Preclinical Results for ARGX-113
Read more →ARGXarGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period
arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period
Read more →ARGXarGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference
arGEN-X to Present at the Wedbush 2014 Life Sciences Management Access Conference
Read more →ARGXarGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels
arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels
Read more →ARGXarGEN-X Launches Initial Public Offering on Euronext Brussels
arGEN-X Launches Initial Public Offering on Euronext Brussels
Read more →ARGXarGEN-X Announces Intention to Launch an Initial Public Offering on Euronext Brussels
arGEN-X Announces Intention to Launch an Initial Public Offering on Euronext Brussels
Read more →ARGXarGEN-X Enters Long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies
arGEN-X Enters Long-term Strategic Alliance with Shire Pharmaceuticals in Therapeutic Antibodies
Read more →ARGXarGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO
arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO
Read more →ARGXarGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates
arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates
Read more →ARGXarGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
Read more →ARGXarGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program
arGEN-X uses its SIMPLE Antibody™ platform to identify four ‘hotspots’ on MET as targets for its therapeutic antibody program
Read more →ARGXarGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board
arGEN-X Appoints Dr Werner Lanthaler to its Supervisory Board
Read more →ARGXarGEN-X receives two preclinical milestone payments under collaboration with Shire
arGEN-X receives two preclinical milestone payments under collaboration with Shire
Read more →ARGXarGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients
arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients
Read more →ARGXARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study
Read more →ARGXarGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B
Read more →ARGXarGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer
Read more →ARGXarGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire
arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire
Read more →ARGXarGEN-X initiates Phase Ib study of ARGX-111 in cancer
arGEN-X initiates Phase Ib study of ARGX-111 in cancer
Read more →ARGXarGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7
arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7
Read more →ARGXarGEN-X grants license to its NHance™ antibody half-life extension technology
arGEN-X grants license to its NHance™ antibody half-life extension technology
Read more →ARGXarGEN-X to Present at Upcoming Ninth Annual PEGS 2013
arGEN-X to Present at Upcoming Ninth Annual PEGS 2013
Read more →ARGXarGEN-X announces preclinical development of ARGX-112 for dermatology
arGEN-X announces preclinical development of ARGX-112 for dermatology
Read more →ARGXarGEN-X initiates Phase Ib study of ARGX-110 in cancer
arGEN-X initiates Phase Ib study of ARGX-110 in cancer
Read more →ARGXarGEN-X expands its therapeutic antibody alliance with Shire
arGEN-X expands its therapeutic antibody alliance with Shire
Read more →ARGXarGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform
Read more →ARGXarGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012
arGEN-X reveals the target and unique mechanism of action of its most advanced preclinical antibody at the PEGS Summit 2012
Read more →ARGXarGEN-X appoints Dr. David L. Lacey to its supervisory board
arGEN-X appoints Dr. David L. Lacey to its supervisory board
Read more →ARGXRuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody
RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody
Read more →ARGXCambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner
Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner
Read more →ARGXarGEN-X granted first US patent covering its unique NHance™ technology
arGEN-X granted first US patent covering its unique NHance™ technology
Read more →ARGXarGEN-X launches NHance™ technology to generate better human antibody therapies
arGEN-X launches NHance™ technology to generate better human antibody therapies
Read more →ARGXarGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
arGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
Read more →ARGXarGEN-X enters into a therapeutic antibody alliance with Shire
arGEN-X enters into a therapeutic antibody alliance with Shire
Read more →ARGXarGEN-X advances a third therapeutic antibody program into preclinical development
arGEN-X advances a third therapeutic antibody program into preclinical development
Read more →ARGXarGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round
arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round
Read more →ARGXarGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets
arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets
Read more →ARGXarGEN-X presents significant progress at Biopharm America 2011
arGEN-X presents significant progress at Biopharm America 2011
Read more →ARGXarGEN-X announces non-exclusive license with BioWa for Potelligent® technology
arGEN-X announces non-exclusive license with BioWa for Potelligent® technology
Read more →ARGXarGEN-X initiates a second pre-clinical development program in under 18 months from start of operations
arGEN-X initiates a second pre-clinical development program in under 18 months from start of operations
Read more →ARGXarGEN-X signs discovery and development alliance with Lilly
arGEN-X signs discovery and development alliance with Lilly
Read more →ARGXarGEN-X appoints Dr Debbie Allen as Senior Director Business Development
arGEN-X appoints Dr Debbie Allen as Senior Director Business Development
Read more →ARGXarGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development
arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development
Read more →ARGXarGEN-X granted broad patent covering its unique simple antibody™ platform
arGEN-X granted broad patent covering its unique simple antibody™ platform
Read more →ARGXarGEN-X concludes EUR 12.5 million Series A financing round
arGEN-X concludes EUR 12.5 million Series A financing round
Read more →ARGXarGEN-X simple antibody™ platform set to transform therapeutic antibody discovery & development
arGEN-X simple antibody™ platform set to transform therapeutic antibody discovery & development
Read more →ARGXarGEN-X opens new R&D facility in Flanders
arGEN-X opens new R&D facility in Flanders
Read more →ARGXarGEN-X raises €9.5 million to put SIMPLE Antibody™ platform to work
arGEN-X raises €9.5 million to put SIMPLE Antibody™ platform to work
Read more →Competitive Position
How ARGX ranks across every disease it competes inCompetitive Position is a premium feature
See how ARGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial